Market Overview

Medytox Selects IQVIA's Enterprise Quality Management Platform, Including SmartSolve®, for Quality and Compliance Management


IQVIA™ (NYSE:IQV) today announced that the global biopharmaceutical
company Medytox has selected IQVIA's Enterprise Quality Management
Solutions (EQMS) platform for quality and compliance management. The
platform uniquely supports Medytox's goals of meeting industry
regulatory requirements and exceeding global quality standards.

IQVIA's EQMS platform includes the market-leading SmartSolve®
application and an integrated suite of quality, regulatory, market
surveillance, and safety compliance solutions. It provides clients with
the first-of-its-kind end-to-end, "molecule-to-market" approach for life
science companies to coordinate their management of varied, constantly
changing global requirements.

"We selected IQVIA because we wanted a proven, effective, e-system
approach that adheres to current Good Manufacturing Practices to manage
our quality management processes across our network of manufacturing
plants within Korea," said Michael Lopez, senior vice president of
Global Quality for Medytox. "We're confident that IQVIA, with its
leading EQMS solutions, local domain expertise and support will enable
us to manage ongoing quality processes, better assess potential risk,
and drive continuous improvement and efficiencies, within our
fast-growing global operations."

The SmartSolveTM platform and EQMS suite are an example of
the purpose-built solutions within the IQVIA Technologies Suite focused
on meeting the needs of its life science customers working in a highly
regulated industry in which the degree of quality and compliance of
every internal process can have far-reaching implications for future

For more information about IQVIA's SmartSolve platform click

About Medytox

Medytox, Inc. is a publicly traded biopharmaceutical company focused on
leveraging its proprietary technologies in the microbial toxin area to
develop innovative biotech products to diagnose and treat diseases.
Medytox, Inc. is the only biopharmaceutical company in the world to have
three different types of botulinum toxin products (Neuronox, INNOTOX,
Coretox), and INNOTOX is the only approved liquid toxin available
anywhere in the world. All Medytox products have been developed by
in-house R&D. Since the approval of Neuronox and INNOTOX, Medytox has
continued its strong growth by maintaining a strong position in medical
aesthetics as well as therapeutic indications associated with movement


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps their customers drive human health outcomes
forward. IQVIA's insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap into a
deeper understanding of diseases, human behaviors and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit

here to subscribe to Mobile Alerts for IQVIA

View Comments and Join the Discussion!